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Abstract:
Objective: Haematopoietic stem cell recipients need central venous catheters (CVCs) for easy administration of intravenous 
fluid, medications, apheresis, or dialysis procedures. However, CVCs may lead to infectious or non-infectious complications 
such as thrombosis. The effect of these complications on transplantation outcome is not clear. This manuscript presents the 
complication rates of double-lumen tunnelled CVCs and their effect on transplantation outcome.
Materials and Methods: Data from 111 consecutive patients, of whom 75 received autologous and 36 received allogeneic 
peripheral blood stem cell transplantations, were collected retrospectively. The data were validated by the Record Inspection 
Group of the related JACIE-accredited transplantation centre.  
Results: Thrombosis developed in 2.7% of recipients (0.9 per 1000 catheter days). Catheter-related infection was identified 
in 14 (12.6%) patients (3.6 per 1000 catheter days). Coagulase-negative Staphylococcus was the most common causative agent. 
Engraftment time, rate of 100-day mortality, and development of grade II-IV graft-versus-host disease were not found to be 
associated with catheter-related complications.  
Conclusion: These results indicate that adverse events related with tunnelled CVCs are manageable and have no negative 
effects on transplant outcome. 
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Özet:
Amaç: Hematopoetik kök hücre nakli alıcıları damar içi mayi, ilaç, aferez ve diyaliz işlemleri için santral venöz kateterlere 
(SVK) ihtiyaç duyarlar. Ancak SVK’ların enfeksiyöz ve tromboz gibi enfeksiyöz olmayan komplikasyonları vardır. Bu 
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Introduction
Haematopoietic stem cell recipients need central venous 
catheters (CVCs) for chemotherapy, parenteral nutrition, and 
blood infusion. A wide range of catheter types can be used. 
However, the type, number of lumens, diameter, and insertion 
site of the catheter should be appropriate for the procedure, 
as these affect the frequency of CVC-related complications 
[1,2,3]. Tunnelled CVC is considered appropriate for 
neutropenic and bone marrow transplant patients. Double-
lumen tunnelled CVCs have a lower risk of infection than non-
tunnelled catheters [4]. These are long-term catheters that 
allow for the simultaneous infusion of physically incompatible 
drugs, blood products, and stem cells. Long-term, continuous 
total parenteral nutrition can be provided via these catheters. 
There is limited literature on the complications of tunnelled 
CVC in haematopoietic stem cell recipients. The effects of 
these complications on the outcome parameters of transplant 
recipients remain to be identified.
This study aimed to determine the frequency of tunnelled 
CVC complications in patients who underwent peripheral 
blood stem cell transplantation and to analyse the effects of 
complications on engraftment time, 100-day mortality, and 
acute graft-versus-host disease (GVHD).
Materials and Methods
Study Plan
This was a retrospective, cross-sectional study; it included 
111 patients who underwent haematopoietic peripheral blood 
stem cell transplantation between May 2011 and January 2013.
Data were collected from a previously authorised and 
validated Hospital Information Management System (Nucleus, 
Monad, Ankara, Turkey). The data were validated by the 
Record Inspection Group of the related department. 
The primary endpoint of the study was the rate of 
catheter-related complications. Haemorrhage, thrombosis, 
and infection data obtained from the record system were 
calculated according to the number of catheterisations and 
per 1000-catheter days. Secondary endpoints were the effects 
of complications on thrombocyte and neutrophil engraftment, 
100-day mortality, and development of acute GVHD.
The study included patients who were considered eligible 
for autologous and allogeneic peripheral blood haematopoietic 
stem cell transplantation by the clinical directors of the 
transplant centre. Patient eligibility was evaluated according 
to the Republic of Turkey Regulations on Tissue and Stem 
Cell Transplantation and FACT-JACIE Standards (version 5.2) 
[5].
Patients who had a purulent skin infection of the chest or 
arm during catheter application, those who had chest trauma, 
those who received radiotherapy in the chest region, and those 
of paediatric age (<16 years) were excluded from the study. 
The study was approved by the Başkent University Research 
Committee.
Timing of Placement, Replacement, or Removal of 
Catheters
Tunnelled CVCs were placed in patients just prior 
to starting a conditioning regime for peripheral blood 
haematopoietic stem cell transplantation. Naturally, these 
CVCs were not used for harvesting peripheral blood cells. 
Clinicians continually reviewed the need for central venous 
access in individual patients. Catheters were replaced only for 
clinical indications like clinical infection or purulence at the 
insertion site. 
Selection and Placement of Catheters
All CVCs were inserted in the Interventional Radiology 
Unit by a radiologist or a specialised nurse only. Complete 
blood count and coagulation tests were performed before 
the procedure for all patients who received a double-lumen, 
18-cm-long, tunnelled CVC (Cath, Medcomp, Harleysville, 
PA, USA). Prophylactic antibiotics at the time of insertion 
of the CVC, in-line filters, or anti-infective/microbial lock 
prophylaxis were not used.
komplikasyonların nakil sürecine etkisi net değildir. Bu çalışma ile çift lümen tünelli santral kateter komplikasyonlarının sıklığı 
ve nakil sürecine etkisi araştırılmıştır. 
Gereç ve Yöntemler: Geriye dönük olarak 75 otolog ve 39 allojeneik periferik kök hücre nakli uygulanan toplam 111 hastanın 
verileri toparlandı. Verilerin doğruluğu JACIE akredite merkezimizin kayıt denetleme grubu tarafından kontrol edildi. 
Bulgular: Olguların %2,7’sinde tromboz gelişti (1000 kateter gününde 0,9). Hastaların 14’ünde (%12,6) kateter ilişkili enfeksiyon 
tesbit edildi (1000 kateter gününde 3,6). Koagulaz negatif Stafilokoklar en sık etken idi. Kateter ilişkili komplikasyonlar ile 
engrafman zamanı, evre II-IV graft versus host hastalığı ve 100 günlük mortalite arasında bir ilişki saptanmadı.  
Sonuç: Sonuçlarımız nakil hastalarında tünelli SVK komplikasyonlarının yönetilebilir olduğunu ve bu komplikasyonların nakil 
üzerine olumsuz bir etki yaratmadığını göstermektedir.     
Anahtar Sözcükler: Tunelli santral venöz kateter, Hematopoietik kök hücre transplantasyonu, Tromboz, Enfeksiyon
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The Interventional Radiology Unit inserted CVCs using an 
ultrasound image-guided percutaneous technique. The right 
internal jugular vein was preferred for first access; however, 
the left internal jugular was used in the case of a problem on 
the right side. The vein was punctured with an 18-G needle 
under ultrasonography guidance [6].
Care of the Catheters
A sterile gauze dressing, secured with adhesive tape, was 
only to be changed by a catheter nurse until sufficient healing 
had taken place (following adherence of the cuff; usually 
within 3 weeks of insertion). During this period, the gauze 
was changed by the catheter nurse at least every 48 h. Flushing 
was used after placement prior to and after fluid infusion or 
injection, and prior to and after blood drawing.
The patients carried responsibility for the catheter 
following hospital discharge.
Culture Collection Procedure
A 10-mL blood sample was collected from the peripheral 
vein and from each lumen of the catheter simultaneously into 
an aerobic blood culture bottle. Culture bottles were incubated 
in a BACTEC 9240 (Becton Dickinson Microbiology Systems, 
Sparks, MD, USA) automatic culture device.
Direct stained preparations were made from blood culture 
bottles, which gave a positive result from the system. The 
cultures used media containing 5% sheep blood and eosin 
methylene blue. Cultures were evaluated after incubation at 
37 °C for 24-48 h.
Conventional methods and BBL crystal identification 
systems (Becton Dickinson Microbiology Systems) were used 
to identify bacteria. Antibiotic sensitivity was determined 
via the Kirby-Bauer disc diffusion method according to the 
recommendations of the Clinical and Laboratory Standards 
Institute.
Identification of Complications
If the same agent grew in the blood culture collected 
from the catheter lumen and the peripheral blood, or if the 
growth in the blood culture collected from the catheter 
lumen occurred 2 h prior to that in peripheral blood, it 
was considered a catheter-related blood-stream infection. 
If erythema, increased temperature, or sensitivity occurred 
within a 2-cm periphery of the insertion site of the catheter, 
it was considered a catheter-exit-site infection, irrespective 
of whether the blood culture contained bacterial growth 
[7]. Thrombosis as detected by Doppler ultrasonographic 
examination was evaluated to obtain more objective and 
reliable data and thus avoid misevaluation.
Statistical Analysis 
Statistical analysis was performed using SPSS 17.0. For 
each continuous variable, normality was checked using 
Kolmogorov-Smirnov and Shapiro-Wilk tests. Comparisons 
between groups were applied using a one-way Student’s t-test 
for normally distributed data, and the Mann-Whitney test was 
used for data not normally distributed. Categorical variables 
between groups were analysed using the chi-square test.
Statistical significance was accepted at p<0.05. 
Results
Transplant patients in the study included 40 females 
(36%) and 71 males (64%), with a median age of 49 years 
(range: 16-64). Of the patients, 75 (67.6%) underwent 
an autologous transplant while 36 (32.4%) underwent an 
allogeneic transplant. Diagnoses and stem cell transplant 
types are presented in Table 1.
All 111 catheters placed in the patients were tunnelled 
central catheters. Of these, 100 (90%) were placed in the 
right internal jugular vein and 11 (10%) in the left internal 
Table 1. Distribution of patients who underwent catheter placement according to primary disease and haematopoietic stem 
cell transplantation type. 
Primary Disease Total, n (%) Allogeneic PBSCT, n Autologous PBSCT, n
Acute myeloblastic leukemia 15 (14) 15 -
Multiple myeloma 50 (45) - 50
Non-Hodgkin’s lymphoma 23 (21) 8 15
Hodgkin’s lymphoma 9 (8) - 9
Acute lymphoblastic leukemia 8 (7) 8 -
Other 6 (5) 5 1
Total 111 (100) 36 75
 
 PBSCT: Peripheral blood stem cell transplantation.
Turk J Hematol 2015;32:51-57 Yeral M, et al: Catheter Problems and Effects on Transplant
54
jugular vein. No catheters were placed in the subclavian veins. 
Catheters placed in the internal jugular veins had a median 
size of 10 F (range: 8-14 F). Total catheter dwell time was 
3322 catheter days. Median catheter dwell time per catheter 
was 26 (range: 15-106) days; the median was 14 (15-85) days 
for autologous transplants and 30 (15-106) days for allogeneic 
transplants (p<0.05). Of the 111 catheters used during bone 
marrow transplantation, 108 (92.7%) were removed when 
they were no longer needed. Two catheters were removed 
due to infection and thrombosis complications, and 1 catheter 
(0.9%) exited spontaneously.
The incidences of tunnelled CVC-related complications in 
transplant recipients are shown in Table 2.
Analysis according to catheterisation day showed 
complications in a total of 26 (23.4%) patients (7.8 
complications per 1000 catheter days). Mild haemorrhage, in 
the form of leakage, was observed in 2 patients (1.8%).
Three of 111 patients developed symptomatic thrombosis 
attack (2.7%), representing a rate of 0.9 per 1000 catheter 
days. Symptomatic thrombosis rates of the autologous and 
allogeneic groups were 2 (2.7%) and 1 (2.8%), respectively. 
Fibrin sheaths, which cause catheter dysfunction, were 
identified in 7 (6.3%) patients (2.1 per 1000 catheter days). 
There was no significant difference between the allogeneic 
and autologous sub-groups in terms of the frequencies of 
catheter-related thrombosis and fibrin sheaths (p>0.05).
Catheter-related infections were identified in 14 (12.6%) 
patients. Of these infections, 2 (1.8%) were considered exit-
site infections. During follow-up, catheter-related blood-
stream infection was detected in 12 (10.8%) patients (3.6 per 
1000 catheter days), which represented 9.3% and 13.9% of 
autologous and allogeneic transplant recipients, respectively. 
One (8.4%) infection was caused by Corynebacterium jeikeium, 
2 (16.6%) were caused by Escherichia coli, and the remaining 
9 catheter-related blood-stream infections (75%) were caused 
by coagulase-negative Staphylococcus spp.
The relationship between complications and catheter 
days was assessed. There was no significant relationship with 
thrombosis (p>0.05), but there was a statistically significant 
relationship between duration of catheter dwelling and 
infection (p<0.05).
Outcome parameters according to type of stem cell 
transplantation are documented in Table 3.
All patients achieved absolute neutrophil counts of 
≥0.5x109/L at a median of day 12 (range: 8-17) and platelet 
counts of ≥20x109/L at a median of day 11 (range: 8-23). In 
the autologous and allogeneic sub-groups, the neutrophil 
engraftment times were 12 (8-17) and 12 (10-17) days, 
respectively; thrombocyte engraftment times were 11 (8-21) 
and 12 (9-23) days, respectively. We observed no significant 
difference between the autologous and allogeneic groups in 
terms of engraftment time (p>0.05). Grade II-IV acute GVHD 
was identified in 4 (11.1%) patients who underwent allogeneic 
stem cell transplants. Analyses showed that infection and 
thrombosis did not delay engraftment times. No evidence 
of acute GVHD was observed in patients who developed 
catheter-related blood-stream infection. The overall 100-day 
mortality rate was 3.6% in all stem cell recipients. None of the 
mortalities were related to catheter complications.
Table 2. The incidences of tunnelled CVC-related 
complications in transplant recipients.
Complications Incidence,
n (%)
Events in 1000 
catheter days,
n
Haemorrhage  2 (1.8)     0.6
Fibrin sheaths  7 (6.3)     2.1
Thrombosis  3 (2.7)     0.9
Infection
  Exit site
  Blood stream
14 (12.6)
 2 (1.8)
12 (10.8)
    4.2
    0.6
    3.6
Total 26 (23.4)     7.8
 
CVC: Central venous catheter.
Table 3. Outcome parameters according to type of stem cell transplantation.
Type of  
Transplantation 
Days until neu.  
engraftment, median (range)
Days until plt.  
engraftment,
median (range)
100-day  
mortality 
rate, n (%)
Autologous    12 (8-17)       11 (8-21)   2 (2.6)
Allogeneic    12 (10-17)       12 (9-23)   2 (5.5)
Total    12 (8-17)       11 (8-23)   4 (3.6)
Neu: neutrophil, plt: platelet.
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Discussion
Tunnelled CVCs differ from other catheters in the sense 
that one part of the catheter remains in subcutaneous tissue 
after the venous entrance level. This tunnel theoretically 
provides stability and serves as a barrier against skin-related 
infections. If high-flow venous access is necessary for the 
patient, and if this vascular access is required for at least 3 
weeks, a tunnelled catheter is preferred. 
Catheters can have some complications. Mechanical 
complications in the early period include conditions such 
as haematoma, haemorrhage, artery adjustments, and 
pneumothorax. Previous studies show that, when implanted 
by experienced personnel using imaging techniques, the 
incidence of complications is low [1,6,8]. In the present study, 
tunnelled central catheters were inserted by experienced staff 
of the Interventional Radiology Unit under ultrasonographic 
guidance. In our study, haemorrhage in the form of leakage 
was observed in 2 catheters as a mechanical complication. 
Leakage was controlled by local compression without further 
intervention. 
A review of the literature showed that infection levels in 
patients with a haematological malignity with tunnelled or 
non-tunnelled CVCs varied from 4.5% to 20.8% [9,10,11]. 
The frequency of infection in patients with haematological 
malignancy was higher than in those with solitary tumours 
[12,13]. In acute myeloid leukemia patients, the catheter-
related bacteraemia rate was 31.5%, and 69.6% had a mortal 
course after stem cell infusion [14]. In a large patient series 
that included mostly acute leukemia patients (690 Hickman 
catheters), catheter-related bacteraemia was found in 2.9 per 
1000 catheter days [15]. The incidence of Hickman catheter-
related infections in cancer patients was reported to be 5.98-
7.2 per 1000 catheter days [16]. In contrast, the incidence 
of catheter-related infections was 2.7% in intensive care 
unit patients who were placed with short-term CVCs (5.9 
per 1000 catheter days) [17]. Our rate of catheter-related 
infections was lower than those in intensive care unit patients 
and haematological and non-haematological malignancy 
patients with temporary CVCs. Blood-stream infection rates 
were similar to those in previous reports of complications 
of tunnelled CVCs. Catheter infection levels in allogeneic 
transplant patients were higher than those in autologous 
catheter patients. This is likely caused by the use of immune 
suppressive agents in allogeneic transplants, catheter use time, 
and more frequent catheter manipulations. Nevertheless, 
there was no significant difference between the 2 groups. 
Two cases of exit-site infections were controlled via local 
treatment and care. A wide spectrum of microorganisms can 
cause catheter-related infections. However, the frequency of 
the agents varies according to catheter placement location and 
type. The primary source of infection is contamination from 
the skin flora of both the patient and healthcare personnel. It 
was reported that 34.1%-50% of catheter-related infections are 
caused by coagulase-negative Staphylococcus, while 9.9%-20% 
are caused by S. aureus [17,18,19,20]. In our study, most of the 
catheter-related infections were caused by coagulase-negative 
Staphylococcus, suggesting that efficient catheter care or 
antimicrobial prophylaxis with levofloxacin for transplantation 
procedure could prevent gram-negative infections.
Fibrin sheath formation around the catheter is one of the 
most important problems that disrupt catheter functions. This 
has been reported to occur in 56% of patients with short-term 
catheters [21,22,23]. A fibrin sheath was identified in 7 of 
our patients. Selective t-PA was infused into the catheter in 5 
patients; mechanical intervention via a guide wire was used in 
the remaining 2 patients. Catheter function was re-established 
in all patients following the procedure.
The type of malignancy, chemotherapy type, catheter type, 
placement location, catheter usage errors, and inappropriate 
care are risk factors for thrombosis. Most cases of catheter-
related thrombosis are asymptomatic. A thrombosis incidence 
of 17%-18% was reported in tunnelled CVCs in solid organ 
tumours [13,24]. The incidence of symptomatic thrombosis is 
1.2%-13% in patients with a haematological malignancy and 
central catheter [25]. We report here much lower thrombosis 
rates than did previous studies on tunnelled or non-tunnelled 
CVCs. All 3 of our thrombosis cases developed 21 days after 
placement of catheters. The type of transplantation had 
no significant effect on the rate of complications. However, 
it should be noted that our series included relatively few 
thrombosis cases. The risk of thrombosis and infection in 
Hickman catheters in patients who underwent chemotherapy 
infusion was approximately 5 times greater than that for 
implanted ports [26]. Despite the lower complication rates, 
that type of catheter cannot be considered in haematopoietic 
peripheral blood stem cell transplantation, especially in 
allogeneic transplants. Therefore, we did not use implanted 
venous catheters in our patients.
Catheter-related complications, mostly infections, can 
lead to local or systemic inflammatory conditions. All 
inflammatory states may contribute to the development of 
GVHD. In this study, catheter-related exit-site or blood-stream 
infections were not remarkable observations in the allogeneic 
transplant recipients who developed grade II-IV GVHD. At the 
100 days of follow-up, 2 patients had been lost due to disease 
progression, 1 due to hepatic veno-occlusive disease, and 1 
due to lung infection. Catheter-related complications had no 
effect on the mortality rate in transplant patients.
Three catheters were removed or exited spontaneously 
before completion of the survey. One catheter in a patient who 
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developed thrombosis was removed because it was not re-
canalised despite thrombolytic treatment. One of the catheters 
exited spontaneously. The other catheter was colonised 
by Corynebacterium jeikeium, which is a hospital-acquired 
microorganism resistant to multiple antimicrobial agents.
In conclusion, double-lumen tunnelled CVC is considered 
appropriate for preparation regimens, medical treatments, 
stem cell infusions, and parenteral support in autologous 
and allogeneic stem cell transplantation patients. Our data 
indicate that the acceptable incidence of complications in 
our case series did not have a negative effect on neutrophil or 
thrombocyte engraftment time and did not increase GVHD 
or mortality rates. However, further prospective multi-centre 
studies of catheter-related complications and early-period 
morbidity and mortality are warranted.
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